# MIPS and QCDR Quality Measures—At a Glance

The Academy identified the 31 MIPS quality measures in Table 11 as those most useful for ophthalmic practices. The 30 QCDR quality measures in Table 12 (see page 31) were developed by the Academy in conjunction with sub-specialty societies for reporting via the IRIS Registry.

**Which quality measures should you report?** If you are reporting quality via IRIS Registry/EHR integration, after the performance year is over, an automated process determines which measures will give you the best score. If you are using other reporting mechanisms, you should skim through these 2 tables to see which measures you are most likely to (a) satisfy the case minimum require-ment of 20 patients, (b) satisfy the 60%-data complete-ness criteria, and (c) achieve a high performance rate. Factors to keep in mind include the following:

**1) Report an outcome measure.** You must include at least 1 outcome measure (or if no outcome measure is available, another type of high-priority measure).

**2) Earn bonus points.** After reporting the initial, man-datory high-priority measure, you earn bonus points for reporting additional high-priority measures and for sub-mitting measures using CEHRT (see page 26).

**3) Watch for topped out measures.** When a measure is topped out, you can typically score 10 points with a perfect performance; but if you are less than perfect, there is a ceiling on the number of achievement points that you can score. For example, if a measure is topped out at less than decile 3 (< d3), the ceiling for a less-than-perfect performance would be 3 points; if it is topped out at decile 3, the ceiling would be 3.9 points; if it is topped out at decile 4, the ceiling would be 4.9 points, etc. Note: Special scoring applies to measure 224, which has a maximum achievement score of 7 points (see page 26), though you also can score high-priority and CEHRT bonus points.

**4) Measure 384, measure 385, and the QCDR measures have no benchmark.** CMS will try to establish a benchmark based on this year's performance data. However, if not enough clinicians report these measures, CMS won't have enough data to create a meaningful benchmark and your maximum score for these measures will be 3 points.

**Learn about each measure.** For each measure in Tables 11 and 12, the Academy has created a detailed web page: Go to aao.org/medicare/quality-reporting-measures.

**Some measures have changed since last year.** Check the measure description to see what you might need to do differently. CMS noted that the following measures have undergone big changes: 110, 128, 226, 238, and 374.

**Some measures are inverse measures.** With an inverse measure, a higher percentage indicates a worse perfor-mance (e.g., Measures 1, 192, 238, 388, IRIS3, IRIS25, IRIS27, IRIS30, IRIS31, IRIS33, and IRIS34).

## Table 11: 30 MIPS Quality Measures—At a Glance

| ID: Measure Title | High-Priority Measure (Bonus Points) | Can Be Reported Via: | | | |
|---|---|---|---|---|---|
| | | IRIS Registry (IR) | | EHR Vendor | Claims |
| | | IR/EHR | IR Web Portal | | |
| **1:** Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) | Intermediate Outcome (+2) | | IR portal | EHR vendor | Claims |
| **12:** Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation | | IR/EHR | IR portal *Topped out at d5* | EHR vendor | Claims *Topped out at d3* |
| **14:** Age-Related Macular Degeneration (AMD): Dilated Macular Examination | | | IR portal *Topped out at d7* | | Claims *Topped out at d3* |
| **18:** Diabetic Retinopathy: Docu-mentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy | | IR/EHR | | EHR vendor | |
| **19:** Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care | Care Coordination (+1) | IR/EHR | IR portal *Topped out at d7* | EHR vendor | Claims *Topped out at < d3* |
| **110:** Preventive Care and Screen-ing: Influenza Immunization* | | IR/EHR | IR portal | EHR vendor | Claims |

## Table 11: 30 MIPS Quality Measures—At a Glance  *Continued from previous page.*

| ID: Measure Title | High-Priority Measure (Bonus Points) | IRIS Registry (IR) | | EHR Vendor | Claims |
| --- | --- | --- | --- | --- | --- |
| | | IR/EHR | IR Web Portal | | |
| **111:** Pneumococcal [Pneumonia] Vaccination Status for Older Adults | | IR/EHR | IR portal | EHR vendor | Claims |
| **117:** Diabetes: Eye Exam | | IR/EHR | IR portal *Topped out at d6* | EHR vendor | Claims *Topped out at d4* |
| **128:** Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan* | | IR/EHR | IR portal | EHR vendor | Claims *Topped out at d8* |
| **130:** Documentation of Current Medications in the Medical Record | Patient Safety (+1) | IR/EHR | IR portal *Topped out at d7* | EHR vendor | Claims *Topped out at d5* |
| **137:** Melanoma: Continuity of Care—Recall System‡ | Care Coordination (+1) | | IR portal *Topped out at d5* | | |
| **138:** Melanoma: Coordination of Care‡ | Care Coordination (+1) | | IR portal *Topped out at d6* | | |
| **140:** Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement | | | IR portal *Topped out at d8* | | Claims *Topped out at d3* |
| **141:** Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% or Documentation of a Plan of Care | Outcome (+2) | | IR portal *Topped out at d7* | | Claims *Topped out at < d3* |
| **191:** Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery | Outcome (+2) | IR/EHR | IR portal *Topped out at d8* | EHR vendor | |
| **192:** Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures | Outcome (+2) | IR/EHR *Topped out at d3* | IR portal *Topped out at d4* | EHR vendor *Topped out at d3* | |
| **224:** Melanoma: Overutilization of Imaging Studies in Melanoma‡ | Efficiency (+1) | | IR portal *Topped out at < d3** | | |
| **226:** Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention* | | IR/EHR | IR portal | EHR vendor | Claims *Topped out at d5* |
| **238:** Use of High-Risk Medications in the Elderly* | Patient Safety (+1) | IR/EHR *Topped out at d7* | IR portal *Topped out at d8* | EHR vendor *Topped out at d7* | |
| **265:** Biopsy Follow-Up | Care Coordination (+1) | | IR portal *Topped out at d6* | | |
| **317:** Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented | | | IR portal | EHR vendor | Claims *Topped out at d8* |
| **318:** Falls: Screening for Future Fall Risk | Patient Safety (+1) | IR/EHR | | EHR vendor | |

*Table continued on next page.*

## Table 11: 30 MIPS Quality Measures—At a Glance     *Continued from previous page.*

| ID: Measure Title | High-Priority Measure (Bonus Points) | Can Be Reported Via: | | | |
| --- | --- | --- | --- | --- | --- |
| | | IRIS Registry (IR) | | EHR Vendor | Claims |
| | | IR/EHR | IR Web Portal | | |
| **374:** Closing the Referral Loop: Receipt of Specialist Report* | Care Coordination (+1) | IR/EHR | | EHR vendor | |
| **384:** Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the OR Within 90 Days of Surgery | Outcome (+2) | | IR portal *Does not have a benchmark* | | |
| **385:** Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery | Outcome (+2) | | IR portal *Does not have a benchmark* | | |
| **388:** Cataract Surgery With Intraoperative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy) | Outcome (+2) | | IR portal *Topped out at <d3* | | |
| **389:** Cataract Surgery: Difference Between Planned and Final Refraction | Outcome (+2) | | IR portal | | |
| **397:** Melanoma Reporting | Outcome (+2) | | IR portal *Topped out at d3* | | Claims *Topped out at d4* |
| **402:** Tobacco Use and Help with Quitting Among Adolescents | | | IR portal | | |
| **419:** Overuse of Neuroimaging for Patients With Primary Headache and a Normal Neurological Examination | Efficiency (+1) | | IR portal *Topped out at d4* | | Claims |

\* Has undergone substantive changes since 2017. † Measure 224 has a maximum achievement score of 7 points (see page 26).
‡ Due to ICD-10 changes on Oct. 1, 2018, just submit the first 9 months of data for measures 137, 138, and 224.

## Table 12: 30 QCDR Quality Measures—At a Glance

**Note:** QCDR measures don't have historic benchmarks. Report 6 measures from Table 11 that have benchmarks and aren't topped out at a low level, and report additional measures from Table 12 for their high-priority bonus points.

| | ID: Measure Title | High-Priority Measure (Bonus Points) | Can Be Reported By: |
| --- | --- | --- | --- |
| **Cataract** | **IRIS27:** Adverse Events After Cataract Surgery | Outcome (+2) | IR Portal, IR/EHR* |
| | **IRIS28:** Regaining Vision After Cataract Surgery | Outcome (+2) | |
| **Cornea** | **IRIS1:** Endothelial Keratoplasty: Postoperative Improvement in Best-Corrected Visual Acuity to 20/40 or Greater | Outcome (+2) | IR Portal, IR/EHR* |
| **Glaucoma** | **IRIS2:** Intraocular Pressure (IOP) Reduction | Outcome (+2) | IR Portal, IR/EHR* |
| | **IRIS3:** Visual Field Progression | Outcome (+2) | IR Portal |
| | **IRIS4:** Intraocular Pressure Reduction Following Laser Trabeculoplasty | Outcome (+2) | IR Portal, IR/EHR* |
| **Neuro-Ophthalmology** | **IRIS20:** Idiopathic Intracranial Hypertension: No Worsening or Improvement of Mean Deviation | Outcome (+2) | IR Portal |

*Table continued on next page.*

## Table 12: 30 QCDR Quality Measures—At a Glance    *Continued from previous page.*

| | ID: Measure Title | High-Priority Measure (Bonus Points) | Can Be Reported By: |
|---|---|---|---|
| **Neuro-Oph-thalmology** | **IRIS21:** Ocular Myasthenia Gravis: Improvement of Ocular Deviation or Absence of Diplopia or Functional Improvement | Outcome (+2) | IR Portal |
| | **IRIS22:** Giant Cell Arteritis: Absence of Fellow Eye Involvement After Treatment | | |
| **Oculo-plastics** | **IRIS5:** Surgery for Acquired Involutional Ptosis: Patients With an Improvement of Marginal Reflex Distance | Outcome (+2) | IR Portal |
| | **IRIS6:** Acquired Involutional Entropion: Normalized Lid Position After Surgical Repair | Outcome (+2) | |
| **Pediatrics/ Strabismus** | **IRIS7:** Amblyopia: Interocular Visual Acuity | Outcome (+2) | IR Portal |
| | **IRIS8:** Surgical Esotropia: Postoperative Alignment | Outcome (+2) | |
| **Refractive** | **IRIS23:** Refractive Surgery: Postoperative Improvement in Uncorrected Visual Acuity of 20/20 or Better | Outcome (+2) | IR Portal, IR/EHR* |
| | **IRIS24:** Refractive Surgery: Postoperative Correction Within +/- 0.5 Diopter of the Intended Correction | Outcome (+2) | IR Portal |
| **Retina** | **Age-Related Macular Degeneration (AMD)** | | |
| | **IRIS10:** Exudative AMD: Loss of Visual Acuity | Outcome (+2) | IR Portal, IR/EHR* |
| | **IRIS11:** Nonexudative AMD: Loss of Visual Acuity | Outcome (+2) | |
| | **IRIS34:** AMD: Disease Progression | Outcome (+2) | |
| | **Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME)** | | |
| | **IRIS9:** DR: Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy | Not a high-priority measure (+0) | IR Portal, IR/EHR* |
| | **IRIS13:** DME: Loss of Visual Acuity | Outcome (+2) | IR Portal, IR/EHR* |
| | **Epiretinal Membrane (ERM)** | | |
| | **IRIS29:** Improved Visual Acuity After ERM Treatment Within 90 Days | Outcome (+2) | IR Portal, IR/EHR* |
| | **IRIS30:** Return to OR Within 90 Days After ERM Surgical Treatment | Outcome (+2) | |
| | **Macular Hole** | | |
| | **IRIS32:** Evidence of Anatomic Closure of Macular Hole Within 90 Days After Surgery as Documented by OCT | Outcome (+2) | IR Portal |
| | **IRIS33:** Return to OR Within 90 Days After Macular Hole Surgery | Outcome (+2) | IR Portal, IR/EHR* |
| **Uveitis** | **IRIS16:** Acute Anterior Uveitis: Post-Treatment Visual Acuity | Outcome (+2) | IR/EHR* |
| | **IRIS17:** Acute Anterior Uveitis: Post-Treatment Grade 0 Anterior Chamber Cells | Outcome (+2) | IR Portal |
| | **IRIS18:** Chronic Anterior Uveitis: Post-Treatment Visual Acuity | Outcome (+2) | IR Portal, IR/EHR* |
| **Resource Use** | **IRIS25:** Adenoviral Conjunctivitis: Avoidance of Antibiotics | Appropriate Use (+1) | IR Portal, IR/EHR* |
| | **IRIS26:** Avoidance or Routine Antibiotic Use in Patients Before or After Intravitreal Injections | Appropriate Use (+1) | IR Portal |
| | **IRIS31:** Avoidance of Genetic Testing for Age-Related Macular Degeneration | Appropriate Use (+1) | |

* You may be able to report this measure via IRIS Registry/EHR integration but only if the IRIS Registry is able to extract the relevant data from your EHR. An initial data mapping process will determine whether this is feasible.